Next Science Ltd (NXS) AI Stock Analysis

• Market Cap: AU$40.97M
• Dividend Yield: N/A
• Average Volume (3M): 221.57K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: -4.27%
• EPS Growth: 33.91%
• Country: AU
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.02
• Shares Outstanding: 292,625,370
• 10 Day Avg. Volume: 236,523
• 30 Day Avg. Volume: 221,575
• PEG Ratio: 0.04
• Price to Book (P/B): 6.03
• Price to Sales (P/S): 0.91
• P/FCF Ratio: -2.43
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.03
• Revenue Forecast (FY): AU$61.17M

• Rating: 48 Neutral
• Price Target: AU$0.14 ▲(2.86% Upside)

Next Science Ltd's overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. While technical analysis indicates positive momentum, the valuation remains unattractive due to negative earnings and lack of dividends. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Innovative Technology

The focus on innovative solutions for chronic wounds and biofilm infections positions Next Science as a leader in niche healthcare markets, potentially driving long-term growth through unique product offerings.

Proprietary Technology

The proprietary Xbio technology provides a competitive edge by disrupting biofilm, enhancing product efficacy, and potentially leading to increased market adoption and licensing opportunities.

Revenue Streams

Diverse revenue streams from direct sales and partnerships enhance market reach and stability, supporting sustainable growth and reducing dependency on single income sources.

Negative Factors

Profitability Challenges

Persistent profitability issues with negative margins indicate challenges in covering operational costs, which could hinder long-term financial health and investment capacity.

Negative Cash Flows

Ongoing negative cash flows suggest operational inefficiencies and potential liquidity issues, limiting the company's ability to invest in growth and innovation.

High Debt Levels

Moderate leverage with high debt levels and negative equity returns can strain financial flexibility, impacting the company's ability to fund future initiatives and manage economic downturns.

Next Science Ltd Business Overview & Revenue Model

Company Description

Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. The company develops its products using Xbio Technology platform. It offers SURGX, an antimicrobial gel designed for surgical infection management; BACTISURE, a wound lavage that is used to remove biofilm; BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site infections. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia.

How the Company Makes Money

Next Science generates revenue through the sale of its medical products, particularly those related to wound care and sinus health. The company markets its products directly to healthcare providers, hospitals, and clinics, leveraging both direct sales and distribution partnerships. Key revenue streams include product sales from its wound care line, which includes advanced dressings and topical solutions, as well as its sinus products aimed at addressing chronic sinusitis. Additionally, Next Science may engage in collaborations or partnerships with larger pharmaceutical companies, allowing for shared resources and expanded market reach, which can further enhance its earnings potential. The company also benefits from intellectual property rights associated with its proprietary technologies, which may provide licensing opportunities and contribute to its revenue.

Next Science Ltd Financial Statement Overview

Summary

Next Science Ltd is facing financial difficulties with persistent losses and negative cash flows. Despite modest revenue growth, the company struggles with severe profitability challenges, as indicated by negative margins and a strained balance sheet.

Income Statement

Next Science Ltd has experienced growth in revenue from 2023 to 2024, with a revenue growth rate of 2.87%. However, the company is facing significant challenges in profitability as indicated by negative EBIT and EBITDA margins. The net profit margin remains negative, highlighting ongoing losses and indicating the company is struggling to cover its operational costs.

Balance Sheet

The balance sheet reveals a strained financial position with a debt-to-equity ratio of 0.72, suggesting moderate leverage but reduced equity base. The return on equity is deeply negative at -307.61%, reflecting substantial losses relative to shareholder equity. The equity ratio stands at 37.37%, indicating a relatively balanced capital structure but a decline from previous years.

Cash Flow

Next Science Ltd's cash flow indicates operational challenges with negative operating and free cash flows. The free cash flow to net income ratio is negative, showing cash outflows persist. There is no positive cash flow growth, implying potential liquidity issues and limited cash generation capability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.82M	22.82M	22.18M	11.71M	8.95M	3.44M
Gross Profit	13.84M	18.44M	16.23M	11.90M	5.94M	2.47M
EBITDA	-6.17M	-9.03M	-14.42M	-12.25M	-9.22M	-11.83M
Net Income	-7.09M	-10.59M	-24.51M	-18.30M	-9.35M	-11.91M
Balance Sheet
Total Assets	9.46M	9.21M	17.90M	18.37M	13.67M	23.49M
Cash, Cash Equivalents and Short-Term Investments	971.24K	1.67M	9.28M	5.11M	7.35M	15.34M
Total Debt	5.30M	2.49M	961.97K	1.22M	275.19K	286.83K
Total Liabilities	10.02M	5.77M	5.08M	6.52M	2.94M	4.70M
Stockholders Equity	-557.03K	3.44M	12.82M	11.85M	10.73M	18.80M
Cash Flow
Free Cash Flow	-4.35M	-8.55M	-15.94M	-17.69M	-8.67M	-14.03M
Operating Cash Flow	-4.32M	-7.96M	-15.06M	-17.01M	-7.98M	-13.26M
Investing Cash Flow	-412.02K	-589.22K	-884.50K	-475.72K	-716.76K	-686.80K
Financing Cash Flow	2.12M	1.75M	20.11M	10.25M	1.43M	10.71M

Next Science Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:NXS, the sentiment is Positive. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.15, and above the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 46.94 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:NXS.

Next Science Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIT	59 Neutral	AU$40.43M	11.30	7.64%	3.28%	0.13%	-12.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXS	48 Neutral	AU$40.97M	―	-289.70%	―	-4.27%	33.91%
MVP	46 Neutral	AU$60.84M	540.00	0.19%	―	17.82%	―
AGH	41 Neutral	AU$19.03M	-1.28	―	―	-47.30%	82.53%
IDT	37 Underperform	AU$22.21M	-2.84	-35.58%	―	45.30%	-24.18%

Next Science Ltd Corporate Events

Next Science Ltd Announces Cessation of Securities

Next Science Ltd announced the cessation of certain securities, including sign-on rights, options, and performance rights, due to unmet conditions. This development may impact the company’s capital structure and could influence stakeholder perceptions regarding the company’s financial strategies and operational focus.

Next Science Completes Major Asset Sale to OSARTIS

Next Science Limited has completed the sale of most of its assets to OSARTIS GmbH for $50 million, with plans to distribute approximately $30 million in net proceeds to shareholders after settling debts and costs. The company has also established transitional agreements to ensure a smooth separation and will seek shareholder approval for the distribution method in a meeting expected to be announced in November 2025.